Incyte Corporation announced title changes for three executives effective March 25, 2026: Pablo J. Cagnoni to President, Incyte and Global Head of Research and Development, replacing William J. Meury as President; Steven H. Stein to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa to Executive Vice President and Head of U.S. Commercial. No changes to compensation arrangements; Matteo Trotta will leave following a transition period.
Key takeaways
Pablo J. Cagnoni appointed President, Incyte and Global Head of Research and Development effective March 25, 2026, replacing William J. Meury who remains CEO and Board member.
Steven H. Stein appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development effective March 25, 2026.
Mohamed Issa appointed Executive Vice President and Head of U.S. Commercial effective March 25, 2026, with expanded responsibility for U.S. Oncology and Immunology.
No changes to compensation for impacted executives: Cagnoni, Stein, Issa, and Meury.
Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, to leave after transition period.
U.S. Oncology and Immunology business units integrated into single U.S. commercial organization.